Immunohistochemical analysis of phosphorylated Smad1/5/8, phosphorylated Smad2 and endoglin in central chondrosarcoma samples. A grade III central chondrosarcoma with highly nuclear phosphorylated Smad1/5/8 (A) and highly nuclear phosphorylated Smad2 (B) is shown. C: grade II central chondrosarcoma with high endoglin expression. Note the positivity of the vessels in the right lower corner. Kaplan-Meier analysis of metastasis-free survival in relation to sum score of tumor biopsies for phosphorylated Smad2 (D) and endoglin / CD105 (E) is shown. High pSmad2 or CD105 designate tumor samples with a sum score higher than 3 for the corresponding antibody and survival is shown with a broken line. Survival for patients with low pSmad2 or CD105 is shown with a solid line. The p-values of corresponding log-rank tests are shown. F. Correlation between endoglin / CD105 expression and phosphorylated Smad1/5/8. The percentages of samples with highly (+) or low (−) phosphorylated Smad1/5/8 among samples with high (+) or low (−) endoglin / CD105 are shown.
Boeuf et al. BMC Cancer 2012 12:488 doi:10.1186/1471-2407-12-488